Study guide

17.3 Type 2 Diabetes & Thyroid Disease in Primary Care

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

17.3 Type 2 Diabetes & Thyroid Disease in Primary Care

Key Takeaways Explain This Topic AI

USPSTF recommends screening adults aged 35 to 70 who are overweight or obese, with BMI thresholds of 25 or 23 in Asian American individuals, repeating every 3 years if normal.

Metformin is foundational first-line therapy, is weight-neutral or weight-reducing, carries no hypoglycemia risk as monotherapy, and requires annual vitamin B12 monitoring.

Annual microvascular surveillance comprises dilated retinal examination, urine albumin-to-creatinine ratio with serum creatinine, and comprehensive foot examination.

Hashimoto thyroiditis produces elevated TSH with low free T4 and anti-thyroid peroxidase antibodies, while Graves disease produces suppressed TSH with elevated free T4 and stimulating TSH receptor antibodies.

Euthyroid status is required for normal ovulation and early fetal neurodevelopment, which makes thyroid assessment part of preconception care.

Last updated: September 2026

Type 2 Diabetes Mellitus: Screening, Diagnosis & Glycemic Targets

Type 2 Diabetes Mellitus (T2DM) is characterized by progressive peripheral insulin resistance accompanied by compensatory hyperinsulinemia and eventual pancreatic beta-cell secretory exhaustion.

USPSTF and ADA Screening Guidelines

USPSTF Recommendation: Screen for prediabetes and type 2 diabetes in asymptomatic adults aged 35 to 70 years who are overweight or obese (BMI ≥25 kg/m², or ≥23 kg/m² in Asian American individuals). Repeat screening every 3 years if normal.

ADA Criteria for Testing Asymptomatic Adults: Screen all individuals starting at age 35, or at any age in adults with BMI ≥25 kg/m² (≥23 kg/m² in Asian Americans) who possess at least one risk factor: first-degree relative with diabetes, high-risk racial/ethnic background (African American, Hispanic, American Indian, Asian American), history of Gestational Diabetes Mellitus (GDM) , history of Polycystic Ovary Syndrome (PCOS) , physical inactivity, hypertension (≥130/80 mm Hg), or dyslipidemia (HDL-C <35 mg/dL or triglycerides >250 mg/dL).

ADA Diagnostic Thresholds

Diagnosis requires two abnormal test results from the same sample or two separate test samples, unless the patient presents with classic hyperglycemic crisis or overt random hyperglycemia.

Diagnostic Test Normal Prediabetes Diabetes Mellitus

Fasting Plasma Glucose (FPG) < 100 mg/dL (5.6 mmol/L) 100 – 125 mg/dL (5.6–6.9 mmol/L) ≥ 126 mg/dL (7.0 mmol/L) (fasting ≥8 hours)

Hemoglobin A1c (HbA1c) < 5.7% (39 mmol/mol) 5.7% – 6.4% (39–47 mmol/mol) ≥ 6.5% (48 mmol/mol) (NGSP-certified assay)

2-Hour 75-g Oral Glucose Tolerance (OGTT) < 140 mg/dL (7.8 mmol/L) 140 – 199 mg/dL (7.8–11.0 mmol/L) ≥ 200 mg/dL (11.1 mmol/L)

Random Plasma Glucose — — ≥ 200 mg/dL (11.1 mmol/L) + classic symptoms (polyuria, polydipsia, unexplained weight loss)

Glycemic Targets

Non-Pregnant Adults: Target HbA1c < 7.0% (53 mmol/mol) for most non-pregnant adults to minimize microvascular complications (retinopathy, nephropathy, neuropathy).

Stringent Target (< 6.5%): Appropriate for newly diagnosed, younger individuals with long life expectancy and no cardiovascular disease, provided it can be achieved without clinically significant hypoglycemia.

Less Stringent Target (< 8.0%): Indicated for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, or extensive comorbid medical conditions.

Preconception Target: Women of reproductive potential should achieve an HbA1c < 6.5% (ideally <6.0%) prior to conception to minimize the risk of congenital cardiac and neural tube defects, spontaneous abortion, and macrosomia.

  • Comprehensive Diabetes Management & Microvascular Surveillance
  • Stepwise Pharmacotherapy

Metformin (Biguanide): Foundational first-line pharmacotherapy alongside lifestyle interventions.

Mechanism: Activates AMP-activated protein kinase (AMPK), inhibiting hepatic gluconeogenesis and increasing peripheral insulin sensitivity in skeletal muscle.

Dosing: Initiate at 500 mg PO daily with the evening meal; titrate slowly by 500 mg weekly up to 1,000 mg PO BID (or 2,000 mg daily of extended-release formulation) to mitigate gastrointestinal side effects (nausea, abdominal cramping, loose stools).

Clinical Profile: Weight-neutral or promotes modest weight loss; zero risk of hypoglycemia as monotherapy. Long-term use is associated with vitamin B12 deficiency ; check annual serum B12 levels.

Renal Thresholds: Contraindicated if eGFR < 30 mL/min/1.73m² due to risk of rare but fatal lactic acidosis. Do not initiate if eGFR is 30–44 mL/min/1.73m²; if already taking and eGFR falls to 30–44, reduce dose by 50%.

GLP-1 Receptor Agonists (GLP-1 RAs; e.g., Semaglutide, Liraglutide, Dulaglutide):

Mechanism: Mimic endogenous incretin glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing postprandial glucagon, delaying gastric emptying, and promoting central satiety.

Indications: Preferred add-on agent for patients with established ASCVD, high cardiovascular risk, or obesity. Produces substantial weight reduction and reduces major adverse cardiovascular events (MACE).

Precautions: Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN 2). Discontinue before conception.

SGLT-2 Inhibitors (e.g., Empagliflozin, Dapagliflozin):

Mechanism: Inhibit sodium-glucose cotransporter-2 in the renal proximal convoluted tubule, blocking glucose and sodium reabsorption to promote urinary glucosuria and osmotic diuresis.

Indications: Preferred in patients with diabetic kidney disease (proteinuria) or heart failure with reduced or preserved ejection fraction. Demonstrates robust nephroprotection and reduces heart failure hospitalizations.

Adverse Effects: Increased incidence of vulvovaginal candidiasis and mycotic genital infections, urinary tract infections, volume depletion, and rare euglycemic diabetic ketoacidosis (euDKA) during periods of physiological stress or fasting.

Annual Triad of Microvascular Complication Surveillance

Certified nurse-midwives must coordinate or directly perform annual microvascular complication screenings for all individuals with type 2 diabetes:

Diabetic Retinopathy: Annual dilated eye examination performed by an optometrist or ophthalmologist to detect microaneurysms, cotton-wool spots, hard exudates, or neovascularization.

Diabetic Nephropathy: Annual spot urine albumin-to-creatinine ratio (uACR) and serum creatinine/eGFR. An elevated uACR (30–299 mg/g indicates microalbuminuria; ≥300 mg/g indicates macroalbuminuria) mandates initiation of an ACE inhibitor or ARB in non-pregnant patients to halt renal functional decline.

Diabetic Peripheral Neuropathy: Annual comprehensive diabetic foot examination :

Visual inspection of skin integrity, erythema, maceration, calluses, and deformities.

Palpation of pedal pulses (dorsalis pedis and posterior tibial) to assess peripheral arterial perfusion.

Loss of Protective Sensation (LOPS) Testing: Evaluated using the 10-gram Semmes-Weinstein monofilament applied perpendicularly to 4 to 10 plantar sites (hallux, 1st, 3rd, 5th metatarsal heads) until the nylon filament buckles.

At least one additional neurological test: vibration perception using a 128-Hz tuning fork over the great toe interphalangeal joint, pinprick testing, or Achilles tendon reflex assessment.

Thyroid Disorders: Hypothyroidism vs. Hyperthyroidism

Thyroid dysfunction disproportionately affects women (female-to-male ratio of 5:1 to 8:1). Euthyroid physiology is critical for normal ovulatory function, fertility, and embryonic neurological development.

Clinical Comparison of Primary Thyroid Disorders

Clinical Domain Primary Hypothyroidism (Hashimoto Thyroiditis) Primary Hyperthyroidism (Graves Disease)

Primary Etiology Autoimmune lymphocytic infiltration and progressive destruction of thyroid parenchyma Autoimmune synthesis of Thyroid-Stimulating Immunoglobulins (TSI) / TRAb that bind and stimulate TSH receptors

Key Symptoms Profound fatigue, lethargy, cold intolerance, unexplained weight gain, severe constipation, dry skin, coarse brittle hair, periorbital edema Heat intolerance, excessive diaphoresis, palpitations, resting tachycardia, tremor, nervousness/anxiety, weight loss with increased appetite, hyperdefecation

Menstrual Changes Oligomenorrhea, amenorrhea, or heavy menstrual bleeding (menorrhagia) due to anovulation and hyperprolactinemia Hypomenorrhea or secondary amenorrhea

Physical Exam Bradycardia, hypothermia, slow hoarse speech, delayed relaxation phase of deep tendon reflexes ( pseudomyotonia ), diffuse firm painless goiter Tachycardia, wide pulse pressure, warm moist velvety skin, fine hand resting tremor, proptosis/exophthalmos , pretibial myxedema

Diagnostic Labs Elevated TSH + Low Free T4 ; (Subclinical: Elevated TSH + Normal Free T4); Positive Anti-TPO antibodies (90%–95%) Suppressed TSH (<0.01–0.1 mIU/L) + Elevated Free T4 and/or Free T3 ; Positive TSI / TRAb antibodies

First-Line Pharmacotherapy Levothyroxine (synthetic T4): Full replacement dose ~1.6 mcg/kg/day (based on ideal body weight). Lower starting dose (25–50 mcg) in elderly or cardiac disease. Thionamides (Antithyroid Drugs): ; - Methimazole (MMI): Preferred in non-pregnant adults and trimesters 2 & 3.; - Propylthiouracil (PTU): Preferred in 1st trimester of pregnancy.; Symptomatic relief: Beta-blockers (propranolol, atenolol) .

Drug Administration Rules Take once daily in the morning on an empty stomach with full glass of water , 30–60 minutes before breakfast. Separate by ≥4 hours from calcium, iron, antacids, or PPIs. Educate on signs of agranulocytosis (fever, severe sore throat). Instruct patient to stop medication immediately and obtain STAT CBC with differential.

Laboratory Surveillance Monitor serum TSH every 6 to 8 weeks until euthyroid, then recheck annually or when symptoms change. Monitor Free T4 and Total T3 every 4 to 6 weeks during active titration, maintaining free T4 at upper normal limit.

Pregnancy Adjustments MANDATORY EMPIRIC DOSE INCREASE: Increase weekly levothyroxine dose by 25% to 30% (take 2 extra tablets weekly) immediately upon positive pregnancy test; recheck TSH q4w. PTU in 1st trimester (minimizes teratogenic aplasia cutis/choanal atresia from MMI); switch to MMI in 2nd trimester (minimizes PTU fulminant hepatotoxicity).